Brief: Shanghai Henlius Biotech Updates On Phase 2 Clinical Trial Of HLX79 Injection
25/03/2025 10:25
March 25 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK: APPLICATION FOR PHASE 2 CLINICAL TRIAL OF HLX79 INJECTION IN COMBINATION WITH HANLIKANG APPROVED BY NMPA Further company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln